Abstract

Selective occlusion of tumor vasculature was tested as a therapy for solid tumors in a mouse model. The formation of blood clots (thrombosis) within the tumor vessels was initiated by targeting the cell surface domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker on tumor vascular endothelial cells. This truncated form of tissue factor (tTF) had limited ability to initiate thrombosis when free in the circulation, but became an effective and selective thrombogen when targeted to tumor endothelial cells. Intravenous administration of the antibody-tTF complex to mice with large neuroblastomas resulted in complete tumor regressions in 38 percent of the mice.

Keywords

Tissue factorAntibodyThrombosisTumor cellsCancer researchPathologyMedicineEndothelial stem cellBiologyImmunologyInternal medicineIn vitro

MeSH Terms

AnimalsAntibodiesBlood CoagulationEndotheliumVascularHistocompatibility Antigens Class IIHumansImmunoconjugatesInjectionsIntravenousMiceMiceInbred BALB CMiceNudeNeuroblastomaThromboplastinTumor CellsCultured

Affiliated Institutions

Related Publications

Publication Info

Year
1997
Type
article
Volume
275
Issue
5299
Pages
547-550
Citations
478
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

478
OpenAlex
9
Influential
371
CrossRef

Cite This

Xianming Huang, Grietje Molema, Steven King et al. (1997). Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature. Science , 275 (5299) , 547-550. https://doi.org/10.1126/science.275.5299.547

Identifiers

DOI
10.1126/science.275.5299.547
PMID
8999802

Data Quality

Data completeness: 81%